{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:38:47Z","timestamp":1790854727344,"version":"4.1.0"},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2010,12,20]],"date-time":"2010-12-20T00:00:00Z","timestamp":1292803200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0015233","type":"journal-article","created":{"date-parts":[[2010,12,20]],"date-time":"2010-12-20T21:09:21Z","timestamp":1292879361000},"page":"e15233","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":45,"title":["Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone"],"prefix":"10.1371","volume":"5","author":[{"given":"Angela","family":"Pennisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Shaughnessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmuel","family":"Yaccoby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2010,12,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.","volume":"88","author":"R Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bcmd.2004.01.001","article-title":"Pathogenesis of myeloma bone disease.","volume":"32","author":"GD Roodman","year":"2004","journal-title":"Blood Cells Mol Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth.","volume":"149","author":"S Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.","volume":"23","author":"A Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref5","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.","volume":"7","author":"LS Rosen","year":"2001","journal-title":"Cancer J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.","volume":"23","author":"RE Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.","volume":"108","author":"M Attal","year":"2006","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcb.20774","article-title":"Role of osteoblast suppression in multiple myeloma.","volume":"98","author":"JP Stewart","year":"2006","journal-title":"J Cell Biochem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.","volume":"108","author":"N Giuliani","year":"2006","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bone.2008.01.027","article-title":"The pathogenesis of the bone disease of multiple myeloma.","volume":"42","author":"CM Edwards","year":"2008","journal-title":"Bone"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10428190903503438","article-title":"Osteoblastogenesis and tumor growth in myeloma.","volume":"51","author":"S Yaccoby","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma-osteoclast interactions as a model.","volume":"64","author":"S Yaccoby","year":"2004","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"7599","DOI":"10.1158\/1078-0432.CCR-05-0523","article-title":"The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype.","volume":"11","author":"S Yaccoby","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.","volume":"104","author":"M Abe","year":"2004","journal-title":"Blood"},{"key":"ref15","first-page":"192","article-title":"Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.","volume":"91","author":"S Yaccoby","year":"2006","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.","volume":"109","author":"S Yaccoby","year":"2007","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2007-03-077685","article-title":"Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.","volume":"111","author":"CM Edwards","year":"2008","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2007-10-120253","article-title":"Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.","volume":"112","author":"YW Qiang","year":"2008","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1210\/edrv-14-6-690","article-title":"Anabolic actions of parathyroid hormone on bone.","volume":"14","author":"DW Dempster","year":"1993","journal-title":"Endocr Rev"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.","volume":"104","author":"RL Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis.","volume":"344","author":"RM Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.","volume":"349","author":"JS Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.","volume":"40","author":"RL Jilka","year":"2007","journal-title":"Bone"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"41342","DOI":"10.1074\/jbc.M502168200","article-title":"Wnt Proteins Prevent Apoptosis of Both Uncommitted Osteoblast Progenitors and Differentiated Osteoblasts by {beta}-Catenin-dependent and -independent Signaling Cascades Involving Src\/ERK and Phosphatidylinositol 3-Kinase\/AKT.","volume":"280","author":"M Almeida","year":"2005","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.","volume":"146","author":"T Bellido","year":"2005","journal-title":"Endocrinology"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cmet.2009.12.007","article-title":"Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation.","volume":"11","author":"J Guo","year":"2010","journal-title":"Cell Metab"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone.","volume":"37","author":"H Keller","year":"2005","journal-title":"Bone"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jcb.20506","article-title":"Effects of parathyroid hormone on Wnt signaling pathway in bone.","volume":"95","author":"NH Kulkarni","year":"2005","journal-title":"J Cell Biochem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"19723","DOI":"10.1074\/jbc.M212226200","article-title":"Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics.","volume":"278","author":"L Qin","year":"2003","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jcb.21626","article-title":"PTH\/cAMP\/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells.","volume":"104","author":"A Suzuki","year":"2008","journal-title":"J Cell Biochem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cmet.2009.07.010","article-title":"T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling.","volume":"10","author":"M Terauchi","year":"2009","journal-title":"Cell Metab"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1101\/gad.1702708","article-title":"Parathyroid hormone signaling through low-density lipoprotein-related protein 6.","volume":"22","author":"M Wan","year":"2008","journal-title":"Genes Dev"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.","volume":"349","author":"E Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/sj.leu.2403513","article-title":"The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells.","volume":"18","author":"K Yata","year":"2004","journal-title":"Leukemia"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","article-title":"Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations.","volume":"92","author":"S Yaccoby","year":"1998","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1182\/blood.V94.10.3576.422k01_3576_3582","article-title":"The proliferative potential of myeloma plasma cells manifest in the SCID-hu host.","volume":"94","author":"S Yaccoby","year":"1999","journal-title":"Blood"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.","volume":"116","author":"S Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1365-2141.2007.06742.x","article-title":"Establishment and exploitation of hyperdiploid and non-hyperdiploid human myeloma cell lines.","volume":"138","author":"X Li","year":"2007","journal-title":"Br J Haematol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma.","volume":"108","author":"F Zhan","year":"2006","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/10428190109057995","article-title":"Expression and in vitro modification of parathyroid hormone-related protein (PTHrP) and PTH\/PTHrP-receptor in human myeloma cells.","volume":"41","author":"T Otsuki","year":"2001","journal-title":"Leuk Lymphoma"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bone.2006.09.002","article-title":"Parathyroid hormone activates phosphoinositide 3-kinase-Akt-Bad cascade in osteoblast-like cells.","volume":"40","author":"T Yamamoto","year":"2007","journal-title":"Bone"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.","volume":"26","author":"AB Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","article-title":"Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.","volume":"278","author":"T Bellido","year":"2003","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1677\/joe.1.06057","article-title":"Parathyroid hormone: past and present.","volume":"187","author":"JT Potts","year":"2005","journal-title":"J Endocrinol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.febslet.2009.11.043","article-title":"PDE4 inhibitor upregulates PTH-induced osteoclast formation via CRE-mediated COX-2 expression in osteoblasts.","volume":"584","author":"H Park","year":"2010","journal-title":"FEBS Lett"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(01)00798-3","article-title":"Parathyroid hormone-dependent signaling pathways regulating genes in bone cells.","volume":"282","author":"JT Swarthout","year":"2002","journal-title":"Gene"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jcb.20438","article-title":"Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray.","volume":"95","author":"JE Onyia","year":"2005","journal-title":"J Cell Biochem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jbmr.53","article-title":"Building bone with a SOST-PTH partnership.","volume":"25","author":"NA Sims","year":"2010","journal-title":"J Bone Miner Res"},{"key":"ref49","article-title":"Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice.","author":"GQ Yao","year":"2010","journal-title":"J Bone Miner Metab"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e7930","DOI":"10.1371\/journal.pone.0007930","article-title":"Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.","volume":"4","author":"HY Choi","year":"2009","journal-title":"PLoS ONE"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcb.21848","article-title":"Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase.","volume":"105","author":"Y Liu","year":"2008","journal-title":"J Cell Biochem"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"27298","DOI":"10.1074\/jbc.M702811200","article-title":"Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription.","volume":"282","author":"M Almeida","year":"2007","journal-title":"J Biol Chem"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cmet.2009.12.009","article-title":"FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice.","volume":"11","author":"E Ambrogini","year":"2010","journal-title":"Cell Metab"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cmet.2010.01.001","article-title":"FoxO1 is a positive regulator of bone formation by favoring protein synthesis and resistance to oxidative stress in osteoblasts.","volume":"11","author":"MT Rached","year":"2010","journal-title":"Cell Metab"},{"key":"ref55","article-title":"EphrinB2 Regulation by Parathyroid Hormone (PTH) and PTHrP Revealed by Molecular Profiling in Differentiating Osteoblasts.","author":"EH Allan","year":"2008","journal-title":"J Bone Miner Res"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood-2009-01-201954","article-title":"The ephrinB2\/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth.","volume":"114","author":"A Pennisi","year":"2009","journal-title":"Blood"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.bone.2009.09.019","article-title":"COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation.","volume":"46","author":"BC Jeong","year":"2010","journal-title":"Bone"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jcp.21661","article-title":"Endogenous FGF-2 is critically important in PTH anabolic effects on bone.","volume":"219","author":"MG Sabbieti","year":"2009","journal-title":"J Cell Physiol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1083\/jcb.145.4.783","article-title":"Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation.","volume":"145","author":"R Serra","year":"1999","journal-title":"J Cell Biol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nm.1979","article-title":"TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation.","volume":"15","author":"Y Tang","year":"2009","journal-title":"Nat Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1517\/13543780903241607","article-title":"Investigating the role of PDGF as a potential drug therapy in bone formation and fracture healing.","volume":"18","author":"S Graham","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1359\/JBMR.051109","article-title":"A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide.","volume":"21","author":"R Lindsay","year":"2006","journal-title":"J Bone Miner Res"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1359\/jbmr.090105","article-title":"Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop.","volume":"24","author":"JP Bilezikian","year":"2009","journal-title":"J Bone Miner Res"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2007-11-124164","article-title":"Role of decorin in the antimyeloma effects of osteoblasts.","volume":"112","author":"X Li","year":"2008","journal-title":"Blood"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","article-title":"Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.","volume":"5","author":"RH Lee","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2220\/biomedres.30.315","article-title":"BRAK\/CXCL14 expression in oral carcinoma cells completely suppresses tumor cell xenografts in SCID mouse.","volume":"30","author":"S Ozawa","year":"2009","journal-title":"Biomed Res"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/j.1349-7006.2008.00787.x","article-title":"Daintain\/AIF-1 promotes breast cancer proliferation via activation of the NF-kappaB\/cyclin D1 pathway and facilitates tumor growth.","volume":"99","author":"S Liu","year":"2008","journal-title":"Cancer Sci"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.","volume":"102","author":"RS Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1210\/en.2009-1488","article-title":"Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.","volume":"151","author":"RS Weinstein","year":"2010","journal-title":"Endocrinology"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21310","article-title":"The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.","volume":"84","author":"A Pennisi","year":"2009","journal-title":"Am J Hematol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.","volume":"131","author":"M Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1210\/en.2006-0848","article-title":"Inhibin A is an endocrine stimulator of bone mass and strength.","volume":"148","author":"DS Perrien","year":"2007","journal-title":"Endocrinology"},{"key":"ref73","first-page":"5571","article-title":"Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo.","volume":"62","author":"MS Bendre","year":"2002","journal-title":"Cancer Res"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1359\/jbmr.2000.15.4.663","article-title":"Essential requirement of BMPs-2\/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin.","volume":"15","author":"E Abe","year":"2000","journal-title":"J Bone Miner Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0015233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,14]],"date-time":"2020-06-14T21:41:35Z","timestamp":1592170895000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0015233"}},"subtitle":[],"editor":[{"given":"Paul A.","family":"Bartell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,12,20]]},"references-count":74,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0015233","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,20]]}}}